1,3-Dimethyl-2-imidazolidinone (DMI) is a cyclic urea derivative that has garnered significant attention due to its versatility as a solvent, catalyst, and reagent in various chemical processes. Its synthesis typically involves the reaction of 1,2-diaminoethane with phosgene or its equivalent, followed by methylation. DMI exhibits excellent solvating properties for a wide range of organic and inorganic compounds, including salts, polymers, and pharmaceuticals. As a catalyst, DMI plays a crucial role in promoting various organic reactions, such as alkylations, acylations, and transesterifications. Notably, its non-nucleophilic nature makes it particularly suitable for reactions involving sensitive functionalities. The unique combination of its physical properties and catalytic activity has led to its widespread application in diverse fields, including polymer synthesis, fine chemical production, and pharmaceutical manufacturing. Extensive research efforts are underway to explore its potential applications in areas such as biomass conversion, green chemistry, and battery technology. The study of DMI is driven by its promising characteristics as a sustainable and efficient tool in organic chemistry, with potential for significant societal impact.'
1,3-dimethyl-2-imidazolidinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6661 |
| CHEMBL ID | 12338 |
| CHEBI ID | 193015 |
| SCHEMBL ID | 3043 |
| MeSH ID | M0587931 |
| Synonym |
|---|
| HMS1775L21 |
| dimethylethyleneurea |
| 1,3-dimethyl-2-imidazolidinone |
| rhonite 1 |
| dimethyl imidazolidinone |
| n,n'-dimethylimidazolidinone |
| einecs 201-304-8 |
| n,n'-dimethylethyleneurea |
| brn 0108808 |
| karbomos tsem |
| n,n'-dimethylimidazolidone |
| 1,3-dimethylethyleneurea |
| 80-73-9 |
| 1,3-dimethyl-2-imidazolidone |
| 2-imidazolidone,1,3-dimethyl |
| 1,3-dimethylimidazolidin-2-one |
| 2-imidazolidinone, 1,3-dimethyl- |
| inchi=1/c5h10n2o/c1-6-3-4-7(2)5(6)8/h3-4h2,1-2h |
| 1,3-dimethyl-2-imidazolidinone, reagent grade |
| 1,3-dimethyl-2-imidazolidinone, absolute, over molecular sieve (h2o <=0.04%), >=99.5% (gc) |
| 1,3-dimethyl-2-imidazolidinone, >=99.0% (gc) |
| CHEMBL12338 |
| dmeu |
| D1477 |
| 1,3-dimethyl-2-imidazolidinon |
| CHEBI:193015 |
| AKOS001025634 |
| A839969 |
| 1,3-dimethylimidazolidone |
| dimethylimidazolidinone |
| ec 201-304-8 |
| 5-24-01-00054 (beilstein handbook reference) |
| unii-5c1yqq9m90 |
| 5c1yqq9m90 , |
| FT-0606688 |
| PS-3257 |
| 1,3-dimethylimidazolidinone |
| dimethyl imidazolidinone [inci] |
| nikkol dmi |
| 1,3-dimethyl-2-imidazolidinone [mi] |
| n,n-dimethylethylenediamine cyclic urea |
| SCHEMBL3043 |
| 1,3-dimethylimidazolin-2-one |
| 1,3-dimethyl imidazolidin-2-one |
| 1,3-di-methyl-2-imidazolidinone |
| 1,3-dimethyl2-imidazolidinone |
| 1,3-dimethyl 2-imidazolidinone |
| 1,3-dimethylimidazolidine-2-one |
| 1.3-dimethyl-2-imidazolidinone |
| n,n'-dimethylimidazoline-2-one |
| 1,3-dimethyl-2-imidazolidone- |
| 1,3-dimethyl-2- imidazolidinone |
| 1,3-dimethyl-imidazolidin-2-one |
| 1,3-dimethyl-imidazolidinone |
| dimethylimidazolidone |
| 1,3-dimetyl-2-imidazolidinone |
| 1,3-dimethyl-imidazolin-2-one |
| STR04040 |
| n,n'-dimethyl-2-imidazolidinone |
| mfcd00003188 |
| DTXSID1073153 , |
| CS-W008767 |
| F0001-2089 |
| 1,3-dimethyl-2-imadazolidinone |
| FT-0700000 |
| Q2463110 |
| AMY25786 |
| 1,3-dimethyl-2-imidazolidinone;1,3-dimethylimidazolidin-2-one;2-imidazolidinone, 1,3-dimethyl-;1,3-dimethyl-2-imidazolidinone 1,3-dimethylimidazolidin-2-one 2-imidazolidinone, 1,3-dimethyl- |
| 1,3-dimethyl-2-imidazolidinone (dmi) |
| D77693 |
| EN300-60599 |
| Z56755571 |
| Class | Description |
|---|---|
| imidazolidinone | An imidazolidine containing one or more oxo groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID71775 | Percent of untreated control cell growth evaluated in friend leukemia cells on day 3 at a concentration of 4 mM | 1981 | Journal of medicinal chemistry, Sep, Volume: 24, Issue:9 | Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation. |
| AID71665 | Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 4 mM | 1981 | Journal of medicinal chemistry, Sep, Volume: 24, Issue:9 | Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation. |
| AID71654 | The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 4 mM | 1981 | Journal of medicinal chemistry, Sep, Volume: 24, Issue:9 | Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||